Gastrointestinal Endoscopy
Volume 71, Issue 1 , Pages 147-166 , January 2010

Endoscopic eradication of Barrett's esophagus

  • Sachin Wani, MD
    • ,
  • Hari Sayana, MD
    • ,
  • Prateek Sharma, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Prateek Sharma, MD, Gastroenterology (111), Department of Veterans Affairs Medical Center, 4801 E. Linwood Blvd., Kansas City, MO 64128-2295.

Received 23 June 2009 ,Accepted 18 July 2009.

References 

  1. Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310–330
  2. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146
  3. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol. 1994;25:982–993
  4. Williamson WA, Ellis FH, Gibb SP, et al. Effect of antireflux operation on Barrett's mucosa. Ann Thorac Surg. 1990;49:537–541discussion 541-2
  5. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut. 1999;45:489–494
  6. Lerut T, Coosemans W, Van Raemdonck D, et al. Surgical treatment of Barrett's carcinoma. Correlations between morphologic findings and prognosis. J Thorac Cardiovasc Surg. 1994;107:1059–1065discussion 1065-6
  7. Heitmiller RF, Redmond M, Hamilton SR. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann Surg. 1996;224:66–71
  8. Konda VJ, Ross AS, Ferguson MK, et al. Is the risk of concomitant invasive esophageal cancer in high-grade dysplasia in Barrett's esophagus overestimated?. Clin Gastroenterol Hepatol. 2008;6:159–164
  9. Oberg S, Johansson J, Wenner J, et al. Metaplastic columnar mucosa in the cervical esophagus after esophagectomy. Ann Surg. 2002;235:338–345
  10. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662–1669
  11. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest. 2006;129:174–181
  12. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. Br Med J. 2004;328:1490
  13. Falck-Ytter Y, Kunz R, Guyatt GH, et al. How strong is the evidence?. Am J Gastroenterol. 2008;103:1334–1338
  14. American Society for Gastrointestinal Endoscopy Technical Committee. Mucosal ablation devices. Gastrointest Endosc. 2008;68:1031–1042
  15. Kantsevoy SV, Adler DG, Conway JD, et al. Endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc. 2008;68:11–18
  16. Petersen BT, Chuttani R, Croffie J, et al. Photodynamic therapy for gastrointestinal disease. Gastrointest Endosc. 2006;63:927–932
  17. Dumot J, Greenwald BD. Argon plasma coagulation, bipolar cautery, and cryotherapy: ABC's of ablative techniques. Endoscopy. 2008;40:1026–1032
  18. Yeh R, Triadafilopoulos G. Endoscopic therapy for Barrett's esophagus. Gastrointest Endosc Clin N Am. 2005;15:377–397
  19. Mork H, Barth T, Kreipe HH, et al. Reconstitution of squamous epithelium in Barrett's oesophagus with endoscopic argon plasma coagulation: a prospective study. Scand J Gastroenterol. 1998;33:1130–1134
  20. Van Laethem JL, Cremer M, Peny MO, et al. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut. 1998;43:747–751
  21. Byrne JP, Armstrong GR, Attwood SE. Restoration of the normal squamous lining in Barrett's esophagus by argon beam plasma coagulation. Am J Gastroenterol. 1998;93:1810–1815
  22. Grade AJ, Shah IA, Medlin SM, et al. The efficacy and safety of argon plasma coagulation therapy in Barrett's esophagus. Gastrointest Endosc. 1999;50:18–22
  23. Pereira-Lima JC, Busnello JV, Saul C, et al. High power setting argon plasma coagulation for the eradication of Barrett's esophagus. Am J Gastroenterol. 2000;95:1661–1668
  24. Schulz H, Miehlke S, Antos D, et al. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc. 2000;51:659–663
  25. Morris CD, Byrne JP, Armstrong GR, et al. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation. Br J Surg. 2001;88:1357–1362
  26. Tigges H, Fuchs KH, Maroske J, et al. Combination of endoscopic argon plasma coagulation and antireflux surgery for treatment of Barrett's esophagus. J Gastrointest Surg. 2001;5:251–259
  27. Kahaleh M, Van Laethem JL, Nagy N, et al. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression. Endoscopy. 2002;34:950–955
  28. Basu KK, Pick B, Bale R, et al. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's oesophagus: factors determining persistence and recurrence of Barrett's epithelium. Gut. 2002;51:776–780
  29. Morino M, Rebecchi F, Giaccone C, et al. Endoscopic ablation of Barrett's esophagus using argon plasma coagulation (APC) following surgical laparoscopic fundoplication. Surg Endosc. 2003;17:539–542
  30. Pagani M, Granelli P, Chella B, et al. Barrett's esophagus: combined treatment using argon plasma coagulation and laparoscopic antireflux surgery. Dis Esophagus. 2003;16:279–283
  31. Familiari L, Scaffidi M, Bonica M, et al. Endoscopic treatment of Barrett's epithelium with argon plasma coagulation. Long-term follow-up. Minerva Gastroenterol Dietol. 2003;49:63–70
  32. Kelty CJ, Ackroyd R, Brown NJ, et al. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther. 2004;20:1289–1296
  33. Hage M, Siersema PD, van Dekken H, et al. 5-Aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut. 2004;53:785–790
  34. Ackroyd R, Tam W, Schoeman M, et al. Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett's esophagus after antireflux surgery. Gastrointest Endosc. 2004;59:1–7
  35. Pinotti AC, Cecconello I, Filho FM, et al. Endoscopic ablation of Barrett's esophagus using argon plasma coagulation: a prospective study after fundoplication. Dis Esophagus. 2004;17:243–246
  36. Dulai GS, Jensen DM, Cortina G, et al. Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus. Gastrointest Endosc. 2005;61:232–240
  37. Pedrazzani C, Catalano F, Festini M, et al. Endoscopic ablation of Barrett's esophagus using high power setting argon plasma coagulation: a prospective study. World J Gastroenterol. 2005;11:1872–1875
  38. Madisch A, Miehlke S, Bayerdorffer E, et al. Long-term follow-up after complete ablation of Barrett's esophagus with argon plasma coagulation. World J Gastroenterol. 2005;11:1182–1186
  39. Sharma P, Wani S, Weston AP, et al. A randomised controlled trial of ablation of Barrett's oesophagus with multipolar electrocoagulation versus argon plasma coagulation in combination with acid suppression: long term results. Gut. 2006;55:1233–1239
  40. Manner H, May A, Miehlke S, et al. Ablation of nonneoplastic Barrett's mucosa using argon plasma coagulation with concomitant esomeprazole therapy (APBANEX): a prospective multicenter evaluation. Am J Gastroenterol. 2006;101:1762–1769
  41. Bright T, Watson DI, Tam W, et al. Randomized trial of argon plasma coagulation versus endoscopic surveillance for Barrett esophagus after antireflux surgery: late results. Ann Surg. 2007;246:1016–1020
  42. Mork H, Al-Taie O, Berlin F, et al. High recurrence rate of Barrett's epithelium during long-term follow-up after argon plasma coagulation. Scand J Gastroenterol. 2007;42:23–27
  43. Ferraris R, Fracchia M, Foti M, et al. Barrett's oesophagus: long-term follow-up after complete ablation with argon plasma coagulation and the factors that determine its recurrence. Aliment Pharmacol Ther. 2007;25:835–840
  44. Formentini A, Schwarz A, Straeter J, et al. Treatment of Barrett's esophagus with argon plasma coagulation and antireflux surgery. A retrospective analysis. Hepatogastroenterology. 2007;54:1991–1996
  45. Bright T, Watson DI, Tam W, et al. Prospective randomized trial of argon plasma coagulation ablation versus endoscopic surveillance of Barrett's esophagus in patients treated with antisecretory medication. Dig Dis Sci. 2008 Dec 20;[Epub ahead of print]
  46. Ragunath K, Krasner N, Raman VS, et al. Endoscopic ablation of dysplastic Barrett's oesophagus comparing argon plasma coagulation and photodynamic therapy: a randomized prospective trial assessing efficacy and cost-effectiveness. Scand J Gastroenterol. 2005;40:750–758
  47. Van Laethem JL, Jagodzinski R, Peny MO, et al. Argon plasma coagulation in the treatment of Barrett's high-grade dysplasia and in situ adenocarcinoma. Endoscopy. 2001;33:257–261
  48. Attwood SE, Lewis CJ, Caplin S, et al. Argon beam plasma coagulation as therapy for high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol. 2003;1:258–263
  49. Sampliner R. Ablative therapies for the columnar-lined esophagus. Gastroenterol Clin North Am. 1997;26:685–694
  50. Sharma P, Bhattacharyya A, Garewal HS, et al. Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus. Gastrointest Endosc. 1999;50:159–164
  51. Montes CG, Brandalise NA, Deliza R, et al. Antireflux surgery followed by bipolar electrocoagulation in the treatment of Barrett's esophagus. Gastrointest Endosc. 1999;50:173–177
  52. Sampliner RE, Faigel D, Fennerty MB, et al. Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study. Gastrointest Endosc. 2001;53:554–558
  53. Barham CP, Jones RL, Biddlestone LR, et al. Photothermal laser ablation of Barrett's oesophagus: endoscopic and histological evidence of squamous re-epithelialisation. Gut. 1997;41:281–284
  54. Salo JA, Salminen JT, Kiviluoto TA, et al. Treatment of Barrett's esophagus by endoscopic laser ablation and antireflux surgery. Ann Surg. 1998;227:40–44
  55. Gossner L, May A, Stolte M, et al. KTP laser destruction of dysplasia and early cancer in columnar-lined Barrett's esophagus. Gastrointest Endosc. 1999;49:8–12
  56. Weston AP, Sharma P. Neodymium:yttrium-aluminum garnet contact laser ablation of Barrett's high grade dysplasia and early adenocarcinoma. Am J Gastroenterol. 2002;97:2998–3006
  57. Fisher RS, Bromer MQ, Thomas RM, et al. Predictors of recurrent specialized intestinal metaplasia after complete laser ablation. Am J Gastroenterol. 2003;98:1945–1951
  58. Bowers SP, Mattar SG, Waring PJ, et al. KTP laser ablation of Barrett's esophagus after anti-reflux surgery results in long-term loss of intestinal metaplasia. Potassium-titanyl-phosphate. Surg Endosc. 2003;17:49–54
  59. Wang K, Lutzke L, Borkenhagen L, et al. Photodynamic therapy for Barrett's esophagus: does light still have a role?. Endoscopy. 2008;40:1021–1025
  60. Ortner MA, Zumbusch K, Liebetruth J, et al. Is topical delta-aminolevulinic acid adequate for photodynamic therapy in Barrett's esophagus? A pilot study. Endoscopy. 2002;34:611–616
  61. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc. 1999;49:1–7
  62. Ackroyd R, Kelty CJ, Brown NJ, et al. Eradication of dysplastic Barrett's oesophagus using photodynamic therapy: long-term follow-up. Endoscopy. 2003;35:496–501
  63. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc. 2003;58:183–188
  64. Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology. 1998;114:448–455
  65. Wolfsen HC, Woodward TA, Raimondo M. Photodynamic therapy for dysplastic Barrett esophagus and early esophageal adenocarcinoma. Mayo Clin Proc. 2002;77:1176–1181
  66. May A, Gossner L, Pech O, et al. Local endoscopic therapy for intraepithelial high-grade neoplasia and early adenocarcinoma in Barrett's oesophagus: acute-phase and intermediate results of a new treatment approach. Eur J Gastroenterol Hepatol. 2002;14:1085–1091
  67. Javaid B. Photodynamic therapy (PDT) for oesophageal dysplasia and early carcinoma with mTHPC (m-tetrahidroxyphenyl chlorin): a preliminary study. Lasers Med Sci. 2002;17:135
  68. Wolfsen HC, Hemminger LL, Wallace MB, et al. Clinical experience of patients undergoing photodynamic therapy for Barrett's dysplasia or cancer. Aliment Pharmacol Ther. 2004;20:1125–1131
  69. Etienne J, Dorme N, Bourg-Heckly G, et al. Photodynamic therapy with green light and m-tetrahydroxyphenyl chlorin for intramucosal adenocarcinoma and high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc. 2004;59:880–889
  70. Lovat LB, Jamieson NF, Novelli MR, et al. Photodynamic therapy with m-tetrahydroxyphenyl chlorin for high-grade dysplasia and early cancer in Barrett's columnar lined esophagus. Gastrointest Endosc. 2005;62:617–623
  71. Pech O, Gossner L, May A, et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc. 2005;62:24–30
  72. Weiss AA, Wiesinger HA, Owen D. Photodynamic therapy in Barrett's esophagus: results of treatment of 17 patients. Can J Gastroenterol. 2006;20:261–264
  73. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62:488–498
  74. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc. 2007;66:460–468
  75. Keeley SB, Pennathur A, Gooding W, et al. Photodynamic therapy with curative intent for Barrett's esophagus with high grade dysplasia and superficial esophageal cancer. Ann Surg Oncol. 2007;14:2406–2410
  76. Dunkin BJ, Martinez J, Bejarano PA, et al. Thin-layer ablation of human esophageal epithelium using a bipolar radiofrequency balloon device. Surg Endosc. 2006;20:125–130
  77. Smith CD, Bejarano PA, Melvin WS, et al. Endoscopic ablation of intestinal metaplasia containing high-grade dysplasia in esophagectomy patients using a balloon-based ablation system. Surg Endosc. 2007;21:560–569
  78. Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc. 2007;65:185–195
  79. Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc. 2008;68:867–876
  80. Ganz RA, Overholt BF, Sharma VK, et al. Circumferential ablation of Barrett's esophagus that contains high-grade dysplasia: a U.S. multicenter registry. Gastrointest Endosc. 2008;68:35–40
  81. Hernandez JC, Reicher S, Chung D, et al. Pilot series of radiofrequency ablation of Barrett's esophagus with or without neoplasia. Endoscopy. 2008;40:388–392
  82. Pouw RE, Gondrie JJ, Sondermeijer CM, et al. Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection. J Gastrointest Surg. 2008;12:1627–1636discussion 1636-7
  83. Roorda AK, Marcus SN, Triadafilopoulos G. Early experience with radiofrequency energy ablation therapy for Barrett's esophagus with and without dysplasia. Dis Esophagus. 2007;20:516–522
  84. Shaheen NJ, Sharma P, Overholt BF, et al. A randomized trial of radiofrequency ablation for Barrett's esophagus with dysplasia. N Engl J Med. 2009;360:2277–2288
  85. Sharma VK, Kim HJ, Das A, et al. A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). Endoscopy. 2008;40:380–387
  86. Johnston M, Eastone JA, Horwat JD, et al. Cryoablation of Barrett's esophagus: a pilot study. Gastrointest Endosc. 2005;62:842–848
  87. Greenwald B, Horwhat JD, Abrams JA, et al. Endoscopic cryoablation is safe and well-tolerated in Barrett's esophagus, esophageal dysplasia and esophageal cancer (abstract). Gastrointest Endosc. 2008;67:AB76
  88. Johnston M, Cash BE, Dykes CA, et al. Cryoablation of dysplasia in Barrett's esophagus (BE) and early stage cancer [abstract]. Gastrointest Endosc. 2006;63:AB223
  89. Dumot J, Vargo JJ, Zuccaro G, et al. Results of cryospray ablation for esophageal high grade dysplasia (HGD) and intramucosal cancer (IMC) in high risk non-surgical patients [abstract]. Gastrointest Endosc. 2008;67:AB176
  90. Inoue H, Endo M, Takeshita K, et al. Endoscopic resection of early-stage esophageal cancer. Surg Endosc. 1991;5:59–62
  91. Giovannini M, Bories E, Pesenti C, et al. Circumferential endoscopic mucosal resection in Barrett's esophagus with high-grade intraepithelial neoplasia or mucosal cancer. Preliminary results in 21 patients. Endoscopy. 2004;36:782–787
  92. Seewald S, Akaraviputh T, Seitz U, et al. Circumferential EMR and complete removal of Barrett's epithelium: a new approach to management of Barrett's esophagus containing high-grade intraepithelial neoplasia and intramucosal carcinoma. Gastrointest Endosc. 2003;57:854–859
  93. Peters FP, Kara MA, Rosmolen WD, et al. Stepwise radical endoscopic resection is effective for complete removal of Barrett's esophagus with early neoplasia: a prospective study. Am J Gastroenterol. 2006;101:1449–1457
  94. Conio M, Repici A, Cestari R, et al. Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett's esophagus: an Italian experience. World J Gastroenterol. 2005;11:6650–6655
  95. Soehendra N, Seewald S, Groth S, et al. Use of modified multiband ligator facilitates circumferential EMR in Barrett's esophagus (with video). Gastrointest Endosc. 2006;63:847–852
  96. Peters FP, Kara MA, Curvers WL, et al. Multiband mucosectomy for endoscopic resection of Barrett's esophagus: feasibility study with matched historical controls. Eur J Gastroenterol Hepatol. 2007;19:311–315
  97. Abrams JA, Fedi P, Vakiani E, et al. Depth of resection using two different endoscopic mucosal resection techniques. Endoscopy. 2008;40:395–399
  98. Nijhawan PK, Wang KK. Endoscopic mucosal resection for lesions with endoscopic features suggestive of malignancy and high-grade dysplasia within Barrett's esophagus. Gastrointest Endosc. 2000;52:328–332
  99. Larghi A, Lightdale CJ, Ross AS, et al. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma. Endoscopy. 2007;39:1086–1091
  100. Lopes CV, Hela M, Pesenti C, et al. Circumferential endoscopic resection of Barrett's esophagus with high-grade dysplasia or early adenocarcinoma. Surg Endosc. 2007;21:820–824
  101. Pech O, Behrens A, May A, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut. 2008;57:1200–1206
  102. Sharma VK, Kim JH, Das A, et al. Circumferential and focal ablation of Barrett's esophagus containing dysplasia. Am J Gastroenterol. 2009;104:310–317
  103. Waxman I, Raju GS, Critchlow J, et al. High-frequency probe ultrasonography has limited accuracy for detecting invasive adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: a case series. Am J Gastroenterol. 2006;101:1773–1779
  104. May A, Gunter E, Roth F, et al. Accuracy of staging in early oesophageal cancer using high resolution endoscopy and high resolution endosonography: a comparative, prospective, and blinded trial. Gut. 2004;53:634–640
  105. Larghi A, Lightdale CJ, Memeo L, et al. EUS followed by EMR for staging of high-grade dysplasia and early cancer in Barrett's esophagus. Gastrointest Endosc. 2005;62:16–23
  106. Sayana H, Wani S, Keighley JD, et al. Endoscopic mucosal resection (EMR) as a diagnostic tool in Barrett's esophagus (BE) patients with high-grade dysplasia (HGD) and early esophageal adenocarcinoma (EAC): a systematic review. Gastroenterology. 2008;134:A-724
  107. Hur C, Nishioka NS, Gazelle GS. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Dig Dis Sci. 2003;48:1273–1283
  108. Shaheen NJ, Inadomi JM, Overholt BF, et al. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis. Gut. 2004;53:1736–1744
  109. Comay D, Blackhouse G, Goeree R, et al. Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis. Can J Gastroenterol. 2007;21:217–222
  110. Peters FP, Kara MA, Rosmolen WD, et al. Endoscopic treatment of high-grade dysplasia and early stage cancer in Barrett's esophagus. Gastrointest Endosc. 2005;61:506–514
  111. Yachimski P, Puricelli WP, Nishioka NS. Patient predictors of histopathologic response after photodynamic therapy of Barrett's esophagus with high-grade dysplasia or intramucosal carcinoma. Gastrointest Endosc. 2009;69:205–212
  112. Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology. 2007;132:1226–1233
  113. Das A, Singh V, Fleischer DE, et al. A comparison of endoscopic treatment and surgery in early esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J Gastroenterol. 2008;103:1340–1345
  114. Wei J, Sharma P, Shaheen NJ. Endoscopic ablation therapies for Barrett's esophagus: a systematic review and meta-analysis of stricture complication. Am J Gastroenterol. 2003;98:S33
  115. Prasad GA, Wang KK, Buttar NS, et al. Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc. 2007;65:60–66
  116. Yachimski P, Puricelli WP, Nishioka NS. Patient predictors of esophageal stricture development after photodynamic therapy. Clin Gastroenterol Hepatol. 2008;6:302–308
  117. Odze R, Lauwers GY. Histopathology of Barrett's esophagus after ablation and endoscopic mucosal resection therapy. Endoscopy. 2008;40:1008–1015
  118. Hornick J, Blount PL, Sanchez CA, et al. Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett's esophagus. Am J Surg Pathol. 2005;29:372–380
  119. Van Laethem J, Peny MO, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut. 2000;46:574–577
  120. Mino-Kenudson M, Ban S, Obana M, et al. Buried dysplasia and early adenocarcinoma arising in Barrett's esophagus after porfimer-photodynamic therapy. Am J Pathol. 2007;31:403–409
  121. Bronner MP, Overholt BF, Taylor SL, et al. Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett's esophagus with high-grade dysplasia. Gastroenterology. 2009;136:56–64
  122. Hornick J, Mino-Kenudson M, Lauwers G, et al. Buried Barrett's epithelium following photodynamic therapy shows reduced crypt proliferation and absence of DNA content abnormalities. Am J Gastroenterol. 2008;103:38–47
  123. Krishnadath KK, Wang KK, Taniguchi K, et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology. 2000;119:624–630
  124. Wani S, Puli SR, Shaheen NJ, et al. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol. 2009;104:502–513
  125. Odze RD. Diagnosis and grading of dysplasia in Barrett's oesophagus. J Clin Pathol. 2006;59:1029–1038
  126. Rastogi A, Puli S, El-Serag HB, et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008;67:394–398
  127. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?. Gastroenterology. 2000;119:333–338
  128. Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol. 2006;4:566–572
  129. Inadomi JM, Sampliner R, Lagergren J, et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med. 2003;138:176–186
  130. Dvorak K, Ramsey L, Payne CM, et al. Abnormal expression of biomarkers in incompletely ablated Barrett's esophagus. Ann Surg. 2006;244:1031–1036
  131. Sharma P, Falk GW, Sampliner RE, et al. Management of non dysplastic Barrett's esophagus: where are we now?. Am J Gastroenterol. 2009;104:805–808
  132. Wani S, Mathur SM, Sharma P. How to manage a Barrett's esophagus patient with low-grade dysplasia. Clin Gastroenterol Hepatol. 2009;7:27–32
  133. Wani S, Falk G, Sampliner RE, et al. Low-grade dysplasia (LGD) is a poor marker for cancer progression in patients with Barrett's esophagus (BE): preliminary results from a large, multicenter, cohort study. Gastroenterology. 2009;136:A592
  134. Montgomery E, Bronner MP, Goldblum JR, et al. Reproducibility of the diagnosis of dysplasia in Barrett's esophagus: a reaffirmation. Hum Pathol. 2001;32:368–378
  135. Stein HJ, Feith M, Mueller J, et al. Limited resection for early adenocarcinoma in Barrett's esophagus. Ann Surg. 2000;232:733–742
  136. Manner H, May A, Pech O, et al. Early Barrett's carcinoma with ”low-risk“ submucosal invasion: long-term results of endoscopic resection with a curative intent. Am J Gastroenterol. 2008;103:2589–2597
  137. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology. 2006;131:1392–1399
  138. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc. 2003;58:S3–43
  139. Endoscopic Classification Review Group. Update on the Paris classification of superficial neoplastic lesions in the digestive tract. Endoscopy. 2005;37:570–578
  140. Prasad GA, Wang KK, Halling KC, et al. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology. 2008;135:370–379

 DISCLOSURE: The following author disclosed financial relationships relevant to this publication: P. Sharma: grant support from Barrx Medical and Olympus. The other authors disclosed no financial relationships relevant to this publication.

 Supported by the Veterans Affairs Medical Center, Kansas City, Missouri.

PII: S0016-5107(09)02268-8

doi: 10.1016/j.gie.2009.07.026

Gastrointestinal Endoscopy
Volume 71, Issue 1 , Pages 147-166 , January 2010

Article Tools